DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 94 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactResults

Ind-Swift Laboratories Limited — Press Release

NSE 1 hr ago·30 Oct 2026, 12:21 pm

IND Swift Laboratories LT

Ind-Swift Laboratories Limited has announced its financial results for the second quarter and the first half of the fiscal year, ending September 30, 2026. The company has filed a formal press release with the stock exchanges to disclose these unaudited standalone and consolidated figures.

For investors, this update is important as it provides the first look at the company's operational performance and financial health for the current period. It helps gauge the company's growth trajectory and efficiency in the pharmaceutical market.

Investors should watch for details on revenue growth, profit margins, and any commentary regarding future business outlook or challenges. This information will be crucial for assessing the company's short-term and long-term investment potential.